There is a growing literature on the benefits of palliative care in serious illness. A number of randomized controlled trials (RCTs) show the benefits of early palliative care in patients with cancer, leading to integration of palliative care into oncology guidelines. [1] [2] [3] [4] One of the first RCTs published in the New England Journal of Medicine by Temel et al. 1 showed that early palliative care yielded improved quality of life, mood, and survival. These authors also described the importance of assessing and cultivating prognostic awareness for those with advanced illness, which is a key component of upstream palliative care. Palliative care then helps patients and families cope with their illness and integrate their goals and values into the medical plan, thereby achieving improved quality of life and better end-of-life outcomes. 5 A more limited literature exists supporting the benefits of palliative care in end-stage liver disease (ESLD), although in recent years there has been an increase in publications on this topic. A simple PubMed search using terms "palliative care and end stage liver disease" yields 83 articles, of which three-quarters were published in the past 8 years. This acceleration of work bodes well for innovation and dissemination of palliative care in liver disease reflected by a recent multi-site intervention funded by the Patient-Centered Outcomes Research Institute. 6 However, more research is needed.
One of the key aspects of integrating palliative care into ESLD is that providing high-quality palliative care requires attention to pristine management of decompensated cirrhosis. Often the best way to address symptoms in ESLD is to provide high-quality cirrhosis care by controlling ascites and related infections, hepatic encephalopathy, and esophageal varices. Unlike many other conditions in which burdensome disease-modifying therapies are reduced or abandoned as palliative care is instituted, standard treatments for liver disease are often maintained as palliative care is insinuated into care for the ESLD patient. For example, a comfort-oriented approach for a patient with ESLD and ascites unresponsive to diuretics who presents with abdominal pain, agitation, and confusion is likely treatment with paracentesis, lactulose, and/or rifaximin and possibly antibiotics to treat spontaneous bacterial peritonitis. Often, an approach to cirrhosis management that includes sparing use of opioids-even for patients at the end of life-will allow a patient to experience improved quality of life and perhaps more meaningful time while being able to interact with family or opportunities to achieve other end-of-life goals. Once the patient can no longer swallow, treatment options are more limited (especially if goals are not in line with nasogastric tube placement) and the focus may transition to managing the symptoms of cirrhosis (agitation, discomfort) rather than the underlying management of cirrhosis itself. This type of patient-centered care is nuanced and requires careful attention to a patient's medical condition, prognosis, and goals of care.
Another aspect of integrating palliative care into treatment of ESLD is the understanding that while most patients want to continue to survive, findings from the SUPPORT study show that these patients identify some conditions (such as living permanently in a coma or with a ventilator or feeding tube) as worse than death. 7 True integration of palliative care in the management of patients with ESLD should prioritize patient values and goals when designing the care plan and encourage patients to build prognostic awareness over time so that they can understand when they are at risk for undesirable outcomes with aggressive interventions and make decisions accordingly throughout the disease trajectory. This may also allow for interventions to support adaptive coping and focus on things that matter most to the patient. 8 Unfortunately, cultivation of prognostic awareness and advance care planning is often inadequate in patients with cirrhosis, and can lead to significant unmet physical, psychological, and social needs such as what is reported in the Hudson et al. 9 paper in this edition of the journal.
One of the areas where more research is needed is how to assess and improve prognostic awareness among patients with ESLD, especially those considered for liver transplant. We know from the cancer literature that oncologists often overestimate prognosis in patients with advanced cancer. 10 We need to understand whether, despite the existence of excellent prognostic tools for ESLD, similar overestimation in prognosis occurs for patients with ESLD, particularly the likelihood of receiving a transplant. Since transplant results in such a dramatic improvement in prognosis and quality of life, patients are often willing to undergo extensive and aggressive treatments for the chance of transplant. Furthermore, the uncertainty associated with transplant evaluation and lack of clarity regarding prognosis are likely to be associated with distress. How to overcome these potential barriers to assessing and cultivating prognostic awareness among patients with ESLD is worthy of further study.
Our team recently published our experience with embedding a palliative care clinician within an oncology clinic and how this was part of a larger coordination effort to build a shared mental model that incorporates palliative care into the routine care of cancer patients across care settings. 11, 12 The paper published in this edition of the journal by Kimbell et al. presents a promising approach to building a similar model in ESLD by integrating a specially trained liver nurse specialist to help coordinate care of patients with advanced liver disease across inpatient and outpatient settings. They found that the intervention was feasible and may have facilitated improved documentation of care plans in the electronic medical record. 13 Because of the nuance and complexity required to provide the highest quality palliative care to patients with ESLD along their disease trajectory, specialty palliative care consultation alone is not the only solution. Palliative care clinicians should lead the way in creating a shared mental model regarding the importance of advance care planning, symptom management, psychosocial support, and realistic information transmission about transplant eligibility and prognosis among all care providers that care for patients with ESLD throughout the trajectory of illness, including primary care providers, hepatologists, and transplant teams. 
